Melodia Therapeutics AG
Next Generation DPP1 Inhibition
Melodia Therapeutics is advancing a next-generation DPP1 inhibitor to transform the treatment of severe neutrophil-driven inflammatory diseases.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
17.09.2025
Seasoned leaders step into key roles at life sciences startups (startupticker.ch)
24.06.2024
Melodia Therapeutics launched with in-licensing deal (startupticker.ch)
No milestones
No Jobs
No videos and documents
No Awards
Melodia Therapeutics AG
Next Generation DPP1 Inhibition
Website:
www.melodiatx.com/
Headquarter:
Basel
Foundation Date:
January 2024
Technology:
- Medtech